Should I buy or sell NeuroOne Medical Technologies stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroOne Medical Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NMTC shares. View NMTC analyst ratings or view top-rated stocks .

What is NeuroOne Medical Technologies' stock price target for 2024?

1 brokerages have issued twelve-month price targets for NeuroOne Medical Technologies' shares. Their NMTC share price targets range from $2.20 to $2.20. On average, they expect the company's stock price to reach $2.20 in the next year. This suggests a possible upside of 91.3% from the stock's current price. View analysts price targets for NMTC or view top-rated stocks among Wall Street analysts .

How have NMTC shares performed in 2024?

NeuroOne Medical Technologies' stock was trading at $1.58 on January 1st, 2024. Since then, NMTC shares have decreased by 27.2% and is now trading at $1.15. View the best growth stocks for 2024 here .

Are investors shorting NeuroOne Medical Technologies?

NeuroOne Medical Technologies saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 365,300 shares, an increase of 133.0% from the March 15th total of 156,800 shares. Based on an average trading volume of 195,400 shares, the short-interest ratio is presently 1.9 days. Currently, 1.7% of the company's shares are sold short. View NeuroOne Medical Technologies' Short Interest .

When is NeuroOne Medical Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our NMTC earnings forecast .

How were NeuroOne Medical Technologies' earnings last quarter?

NeuroOne Medical Technologies Co. (NASDAQ:NMTC) issued its quarterly earnings data on Tuesday, February, 13th. The company reported ($0.14) earnings per share (EPS) for the quarter. The business earned $0.98 million during the quarter. NeuroOne Medical Technologies had a negative net margin of 478.41% and a negative trailing twelve-month return on equity of 267.82%.

How do I buy shares of NeuroOne Medical Technologies?

Shares of NMTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NMTC

NeuroOne Medical Technologies (NMTC) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free NMTC Stock Alerts

$1.15

+0.01 (+0.88%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.14
▼
$1.17
50-Day Range: $1.03
▼
$1.45
52-Week Range: $0.85
▼
$2.00

Volume: 19,293 shs
Average Volume: 179,803 shs
Market Capitalization: $29.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.20

Get NeuroOne Medical Technologies alerts:

NeuroOne Medical Technologies MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 91.3% Upside
$2.20 Price Target
Short Interest: Healthy
1.66% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.91 out of 5 stars

Medical Sector

800th out of 911 stocks

Surgical & Medical Instruments Industry

83rd out of 97 stocks

3.5

Analyst's Opinion

Consensus Rating
NeuroOne Medical Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
NeuroOne Medical Technologies has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.66% of the float of NeuroOne Medical Technologies has been sold short.
Short Interest Ratio / Days to Cover
NeuroOne Medical Technologies has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NeuroOne Medical Technologies has recently increased by 132.97%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
NeuroOne Medical Technologies does not currently pay a dividend.
Dividend Growth
NeuroOne Medical Technologies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NMTC.

1.1

News and Social Media Coverage

Search Interest
1 people have searched for NMTC on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added NeuroOne Medical Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NeuroOne Medical Technologies insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.50% of the stock of NeuroOne Medical Technologies is held by insiders.
Percentage Held by Institutions
Only 16.07% of the stock of NeuroOne Medical Technologies is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of NeuroOne Medical Technologies is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NeuroOne Medical Technologies is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NeuroOne Medical Technologies has a P/B Ratio of 4.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About NeuroOne Medical Technologies Stock (NASDAQ:NMTC)

NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

NMTC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NMTC Stock News Headlines

April 11, 2024 | stockhouse.com

NeuroOne® Announces First Implant of OneRF(TM) Ablation Electrodes

April 10, 2024 | globenewswire.com

NeuroOne® CEO Dave Rosa Featured on Bloomberg Technology

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 9, 2024 | globenewswire.com

NeuroOne® Announces First Implant of OneRF™ Ablation Electrodes

April 4, 2024 | finance.yahoo.com

NeuroOne® CEO Dave Rosa Featured on Fox Business Network’s Varney & Co.

April 4, 2024 | globenewswire.com

NeuroOne® CEO Dave Rosa Featured on Fox Business Network's Varney & Co.

March 28, 2024 | stockhouse.com

NeuroOne® Initiates Limited Commercial Launch of OneRF(TM) Ablation System

March 26, 2024 | finance.yahoo.com

NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 22, 2024 | investing.com

Neuroone Medical Technologies Corp (NMTC)

March 17, 2024 | ca.finance.yahoo.com

NMTC Jul 2024 2.500 call

March 8, 2024 | globenewswire.com

NeuroOne® to Participate in the 36th Annual Roth Conference

February 24, 2024 | finanznachrichten.de

NeuroOne Medical Technologies Corp: NeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 23, 2024 | globenewswire.com

NeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 16, 2024 | finanznachrichten.de

NeuroOne Medical Technologies Corp: NeuroOne Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

February 16, 2024 | finance.yahoo.com

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2024 Earnings Call Transcript

February 16, 2024 | seekingalpha.com

NeuroOne Medical Technologies Corporation (NMTC) Q1 2024 Earnings Call Transcript

February 15, 2024 | markets.businessinsider.com

NeuroOne Medical Technologies Corporation Registered Shs

February 15, 2024 | finance.yahoo.com

NeuroOne Medical Technologies First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line

February 13, 2024 | msn.com

NeuroOne Medical Technologies GAAP EPS of -$0.14

February 13, 2024 | finance.yahoo.com

NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

February 12, 2024 | markets.businessinsider.com

NeuroOne Medical Technologies earnings: here's what Wall Street expects

February 8, 2024 | finance.yahoo.com

NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13

January 24, 2024 | wsj.com

NeuroOne Medical Technologies Corp.

December 19, 2023 | finance.yahoo.com

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q4 2023 Earnings Call Transcript

December 15, 2023 | finanznachrichten.de

NeuroOne Medical Technologies Corp: NeuroOne Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update

December 14, 2023 | finance.yahoo.com

NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update

See More Headlines

Receive NMTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroOne Medical Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/13/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:NMTC
CUSIP: N/A
CIK: 1500198
Web: www.originalsourcemusic.com
Phone: (952) 426-1383
Fax: N/A
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.20
High Stock Price Target: $2.20
Low Stock Price Target: $2.20
Potential Upside/Downside: +93.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.68)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,860,000.00
Net Margins: -478.41%
Pretax Margin: -478.37%
Return on Equity: -267.82%
Return on Assets: -200.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.68
Quick Ratio: 2.52

Sales & Book Value

Annual Sales: $1.95 million
Price / Sales: 15.16
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.26 per share
Price / Book: 4.38

Miscellaneous

Outstanding Shares: 25,930,000
Free Float: 23,986,000
Market Cap: $29.56 million
Optionable: Optionable
Beta: 0.81

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. David A. Rosa M.D. (Age 60)
President, CEO & Director
Comp: $759.98k
Mr. Ronald W. McClurg (Age 64)
Chief Financial Officer
Comp: $358.79k
Mr. Steven Mertens (Age 61)
Chief Technology Officer
Comp: $332.26k
Mr. Mark Christianson (Age 57)
Co-Founder, Business Development Director & Medical Sales Liaison
Comp: $260.85k
Mr. Christopher R. Volker CFA
Chief Operating Officer
Mr. Hijaz Haris
Vice President of Marketing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NMTC Stock Analysis - Frequently Asked Questions

Should I buy or sell NeuroOne Medical Technologies stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroOne Medical Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NMTC shares.
View NMTC analyst ratings or view top-rated stocks.
What is NeuroOne Medical Technologies' stock price target for 2024?: 1 brokerages have issued twelve-month price targets for NeuroOne Medical Technologies' shares. Their NMTC share price targets range from $2.20 to $2.20. On average, they expect the company's stock price to reach $2.20 in the next year. This suggests a possible upside of 91.3% from the stock's current price.
View analysts price targets for NMTC or view top-rated stocks among Wall Street analysts.
How have NMTC shares performed in 2024?: NeuroOne Medical Technologies' stock was trading at $1.58 on January 1st, 2024. Since then, NMTC shares have decreased by 27.2% and is now trading at $1.15.
View the best growth stocks for 2024 here.
Are investors shorting NeuroOne Medical Technologies?: NeuroOne Medical Technologies saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 365,300 shares, an increase of 133.0% from the March 15th total of 156,800 shares. Based on an average trading volume of 195,400 shares, the short-interest ratio is presently 1.9 days. Currently, 1.7% of the company's shares are sold short.
View NeuroOne Medical Technologies' Short Interest.

When is NeuroOne Medical Technologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our NMTC earnings forecast.
How were NeuroOne Medical Technologies' earnings last quarter?: NeuroOne Medical Technologies Co. (NASDAQ:NMTC) issued its quarterly earnings data on Tuesday, February, 13th. The company reported ($0.14) earnings per share (EPS) for the quarter. The business earned $0.98 million during the quarter. NeuroOne Medical Technologies had a negative net margin of 478.41% and a negative trailing twelve-month return on equity of 267.82%.
How do I buy shares of NeuroOne Medical Technologies?: Shares of NMTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NMTC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial